RELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS OF TINZAPARIN (LOGIPARIN), A LOW-MOLECULAR-WEIGHT HEPARIN, IN DOGS

被引:11
作者
BRINDLEY, CJ [1 ]
TAYLOR, T [1 ]
DINESS, V [1 ]
OESTERGAARD, PB [1 ]
CHASSEAUD, LF [1 ]
机构
[1] NOVO NORDISK AS, DK-2880 BAGSVAERD, DENMARK
关键词
D O I
10.3109/00498259309059396
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Pharmacodynamic models relating the plasma concentrations (C) of radioactive heparin material to anticoagulant effect (E) have been investigated after single i.v. and s.c. doses of H-3-tinzaparin (1 and 4 mg/kg), a radiolabelled low molecular weight heparin, to six dogs. 2. A counterclockwise hysteresis, characterizing the C versus E relationship, was observed in all animals after s.c., but not i.v., doses indicating a possible delay (lag-time) in the systemic availability of pharmacologically-active heparin material following extra-vascular administration. A constant (K(e)) was introduced into the model to account for this hysteresis. 3. At high plasma concentrations of radioactivity (> 10 mug/ml), E was related to C by a sum of two sigmoid E(max) models, whereas, at lower concentrations, this reduced to the well-known sigmoid E(max) model. It was proposed that tinzaparin activates two 'receptors' having different affinities for the drug. The values of EC50 associated with the activation of a single 'receptor' and of a proposed additional 'receptor' were 3 and 13 mug/ml of heparin material, respectively. 4. Heparin material was predominantly eliminated by renal excretion and underwent widespread tissue distribution. After s.c. administration, input of heparin material into systemic plasma was complete within 12h post-dose, and the absorption process was characterized by a bi-exponential function. 5. We conclude that sigmoid E(max) models adequately describe the C versus E relationship after s.c. and i.v. doses of H-3-tinzaparin in dogs and that the interindividual variation of the pharmacodynamic parameters derived from this model was relatively small.
引用
收藏
页码:575 / 588
页数:14
相关论文
共 38 条
[1]  
AARONS L, 1986, ACTA PHARMACOL TOX, V59, P55
[2]   EVALUATION OF A COMPUTER-ASSISTED METHOD FOR INDIVIDUALIZED ANTICOAGULATION - RETROSPECTIVE AND PROSPECTIVE STUDIES WITH A PHARMACODYNAMIC MODEL [J].
ABBRECHT, PH ;
OLEARY, TJ ;
BEHRENDT, DM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (01) :129-136
[3]  
Akaike H., 1976, MATH SCI, V14, P5
[4]   COMPARATIVE PHARMACOKINETICS OF A LOW-MOLECULAR WEIGHT HEPARIN (PK-10-169) AND UNFRACTIONATED HEPARIN AFTER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION [J].
BARA, L ;
BILLAUD, E ;
GRAMOND, G ;
KHER, A ;
SAMAMA, M .
THROMBOSIS RESEARCH, 1985, 39 (05) :631-636
[5]   CORRELATION BETWEEN ANTI-XA AND OCCURRENCE OF THROMBOSIS AND HEMORRHAGE IN POSTSURGICAL PATIENTS TREATED WITH EITHER LOGIPARIN(R) (LMWH) OR UNFRACTIONATED HEPARIN [J].
BARA, L ;
LEIZOROVICZ, A ;
PICOLET, H ;
SAMAMA, M .
THROMBOSIS RESEARCH, 1992, 65 (4-5) :641-650
[6]   HEPARIN HALF-LIFE AND SENSITIVITY IN NORMAL SUBJECTS AND IN PATIENTS AFFECTED BY DEEP-VEIN THROMBOSIS [J].
BENCHEKROUN, S ;
EYCHENNE, B ;
MERICQ, O ;
COLOMBANI, A ;
DOUSTEBLAZY, P ;
BARRET, A ;
SIE, P ;
BONEU, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1986, 16 (06) :536-539
[7]   THE DISAPPEARANCE OF A LOW-MOLECULAR-WEIGHT HEPARIN FRACTION (CY-216) DIFFERS FROM STANDARD HEPARIN IN RABBITS [J].
BONEU, B ;
BUCHANAN, MR ;
CARANOBE, C ;
GABAIG, AM ;
DUPOUY, D ;
SIE, P ;
HIRSH, J .
THROMBOSIS RESEARCH, 1987, 46 (06) :845-853
[8]  
BONEU B, 1989, ANN NY ACAD SCI, V556, P282
[9]  
BRIANT L, 1989, THROMB HAEMOSTASIS, V61, P348
[10]   LINEAR-SYSTEMS ANALYSIS IN PHARMACOKINETICS [J].
CUTLER, DJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (03) :265-282